Mirum Pharmaceuticals (MIRM) Cash from Investing Activities (2019 - 2026)

Mirum Pharmaceuticals' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$11.6 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 28.29% year-over-year to -$11.6 million in Q1 2026; TTM through Mar 2026 was -$19.4 million, a 81.75% increase from a year earlier, with the FY2025 full-year figure at -$24.0 million, up 73.42% from the prior year.
• Cash from Investing Activities fell to -$11.6 million in Q1 2026 per MIRM's latest filing, from $1.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $50.5 million in Q2 2023 and bottomed at -$182.8 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is -$2.0 million (2023), against an average of -$13.2 million.
• Across the five-year window, Cash from Investing Activities soared 211.33% in 2022 and tumbled 124007.69% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $26.8 million in 2022, then slumped by 107.47% to -$2.0 million in 2023, then jumped by 132.05% to $641000.0 in 2024, then surged by 56.94% to $1.0 million in 2025, then sank by 1250.0% to -$11.6 million in 2026.
• Per Business Quant, the three latest MIRM Cash from Investing Activities figures stand at -$11.6 million (Q1 2026), $1.0 million (Q4 2025), and -$2.2 million (Q3 2025).